Hidradenitis suppurativa is associated with increased risks of depression and anxiety across all treatment levels, highlighting the importance of proactive psychiatric screening in dermatologic care.
Patients with psoriatic arthritis consistently identify nonjoint symptoms such as dactylitis, psoriasis, and uveitis, demonstrating the clinical utility of patient-reported outcome measures.
A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
This clinical trial summary highlights the efficacy, safety, and sustained scalp clearance achieved with guselkumab for moderate to severe scalp psoriasis in patients with skin of color.
As Trump’s health officials push personal responsibility, critics warn their rhetoric blames patients, shapes policy, and risks deepening health inequalities.
A woman with a decades-long history of intensely pruritic, nonblistering papules on her extremities was diagnosed with dystrophic epidermolysis bullosa pruriginosa, confirmed by COL7A1 gene sequencing, after a comprehensive clinicopathologic evaluation.
Researchers assess how disease type, comorbidities, and treatment knowledge shape clinical outcomes and healthcare use in patients with chronic urticaria.